HOME > BUSINESS > Govt plans to make India pharma R&D hub in 4 years

Govt plans to make India pharma R&D hub in 4 years

mediThe government is preparing for multi-billion dollar investment to push India into top five pharmaceutical innovation hubs by 2020, Assocham said.

The goal of the program will be for the country to establish global presence in pharmaceutical research by launching at a global level 1 out of every 5-10 drugs discovered in the country, the industry association added.

The effort will be with 50% public funding through its public private partnership (PPP), it said.

The Indian Government has been very active in boosting growth and investment in Indian pharmaceutical industry.

It allows 100 per cent FDI (Foreign Direct Investment) under automatic route (without prior permission) in the pharmaceuticals sector.

“FDI favourably impacts the Indian pharma industry by providing access to more capital/funds for investing in R&D, which in turn, leads to creation of more IPR,” found a study titled ‘IPR in pharmaceuticals: Balancing, innovation and access,’ jointly conducted by ASSOCHAM and TechSci Research.

The Government has been actively undertaking policy initiatives for growth of the pharmaceutical industry.

One such initiative is tax-breaks in the pharmaceutical sector. There is also a weighted tax deduction at a rate of 150% for the research and development expenditure incurred. Steps to streamline methods for development of a new drug molecule, or clinical research, etc., have also been considered.

Indian Government also launched two schemes including New Millennium Indian Technology Leadership Initiative in 2003, and the Drugs and Pharmaceuticals Research Programme in 1994-95, specially targeted at pharmaceutical research, adds the study.

The Department of Industrial Policy and Promotion (DIPP) data suggests that the drugs and pharmaceuticals sector in India has attracted FDI worth USD 1,523 million during April 2014-March 2015.

Additionally, industrial licenses are not essential in India for most of the pharmaceutical products. Hence, drug manufacturers are free to develop any drug upon approval by the Drug Control Authority.

“The act of protecting one’s innovation through a patent has initiated investments from many multinational pharmaceutical companies in India. These MNCs are looking at India for its strength in contract manufacturing and as an attractive base for research and development (R&D), particularly for conducting clinical trials and other services,” Assocham said.

Indian and foreign pharmaceutical companies are progressing with rising patented drug launches in India. The Indian Patent Office granted 2008 patents between 2010 and 2013.

The Department of Pharmaceuticals has drafted Pharma Vision 2020 document, with an aim to establish India as a leading county for end-to-end drug manufacturing and innovation. This initiative by the government aims at providing support to Indian pharmaceutical sector through state of- the-art infrastructure, internationally competitive scientific research personnel for pharmaceutical R&D, and funding for research in the public and private sectors.

The Central Drug Standard Control Organisation (CDSCO), which falls under the scope of the Ministry of Health and Family Welfare, is the main pharma regulatory body in India. The Drug Controller General of India (DCGI) presides over the CDSCO at both the central and state levels.

Sun Pharmaceuticals acquired Ranbaxy Laboratories in 2015, in order to achieve full compliance with regulatory framework for drug manufacturing in India, meet expectations of Indian regulatory authorities, and increase R&D for launch of innovative products, thereby generating high revenues across India.

Follow ULTRA.news
Cipla redraws Iran plans with new agreement, to invest Rs 121 cr Cipla said its wholly owned subsidiary of the Company in Netherlands will set up a 75% joint venture with Ahran Tejarat Company for manufacturing and marketing of pharmaceutical products in Iran.An earlier agreement executed by the Company with the Iranian firm has been termi...
Bliss GVS Healthcare wins three-year contract worth Rs 760 cr from Kenya Bliss GVS Healthcare Ltd said it won a three year contract worth $111.40 mln (Rs 760 cr) from Aon Kenya Insurance Brokers Ltd for provision of medical health care services in Kenya. Bliss GVS Pharma Ltd is a pharmaceutical company based in Mumbai, India.Bliss GVS...
Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta ta...
Demonetization not enough to clean up real estate, says Assocham The ongoing crack down on black money alone will not be helpful to remove black money from the real estate sector, industry union ASSOCHAM said.Many buyers of real estate prefer to show lower costs on record simply to avoid the high levels of stamp duties payable on such tran...
Lupin launches injectable iron formulations in India Pharma major Lupin Limited said it launched Iron Isomaltoside injectable iron formulation under two brand names “Isofer” and “Jilazo” in India.Lupin acquired the exclusive rights to market, distribute and sell the injectable formulation from Denmark based Pharmacosmos A/S.The...
Dr Reddy’s Labs launches osteoporosis drug in the US Dr Reddy's Laboratories Ltd said it launched raloxifene hydrochloride tablets --used to treat osteoporosis -- in the US market.Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharm...
Sun Pharma to get dengue vaccine technology from ICGEB Pharma major Sun Pharma said it tied up with research organization International Centre for Genetic Engineering and Biotechnology to develop vaccines for dengue.The vaccine is targeted against all the four serotypes of Dengue virus that cause disease in humans and is being de...
Aarti Industries to return Rs 96 cr to shareholders via buyback Speciality Chemicals company Aarti Industries Ltd said it will buy back12 lakh equity shares at Rs 800 each, aggregating to Rs 96 cr.The company´s Board of Directors approved the equity shares -- representing up to 1.44% of the company's base."The public announcement sett...
Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets Marksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules -- a synthetic equivalent of Vitamin D.Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in t...
India overdependent on China for medicines – study India may have emerged as a key supplier of generic and affordable medicine for the world market, but it has an "overwhelming dependence" on China for the raw material required to produce these drugs, industry association Assocham said.Indian companies depend on China to supp...
Lupin licenses taste-masking technology from Monosol for paediatric tablets Pharma Major Lupin Ltd. said its US subsidiary, Lupin Pharmaceutical Inc., has agreed to license technology from Monosol Rx to develop multiple paediatric-focused products.Lupin would develop the pediatric products utilizing MonoSol Rx’s proprietary PharmFilm drug delivery ...
Cadila to launch immunosuppressant drug in India Cadila Healthcare, a Ahmedabad headquartered pharmaceutical company owned by Zydus Group, said it has partnered with Switzerland-based global biopharmaceutical company Neovii to launch an drug to reduce the strength of the body's immune system in India.The drug named Grafalon...
Almebic Pharmaceuticals receives inspection report from USFDA Alembic Pharmaceuticals Ltd., said it received an Establishment Inspection Report from the United States Food and Drug Administration for the inspection carried out at their formulation facility at Panelav, Gujarat.The FDA has the authority to inspect any establishment in whi...
Shilpa Medicare receives USFDA approval for generic bone marrow drug Shilpa Medicare Ltd said it received an approval from the United states Food & Drug Administration for Azacitidine injection.Azacitidine is used to treat myelodysplastic syndrome - a group of conditions in which the bone marrow produces blood cells that are misshapen and ...
FDA observations ‘primarily procedural’ – USFDA issued four observations about Cipla's manufacturing facilities in Goa after conducting an audit, the company said. Cipla has three facilities in Goa."The observations were primarily procedural in nature and the company has already responded to these observations," said...
Indians await Amazon, Flipkart offers for Diwali purchases – survey The upcoming festive season, beginning October 1 is likely to register record-breaking sales, revenues, and highest ever purchase rate per minute for e-commerce giants as most people have deferred their holiday purchasing plans in anticipation of blockbuster offers, an ASSOCHAM s...
Lupin receives FDA approval for generic Namenda XR dementia capsules Pharma Major Lupin Ltd said it received final approval from United States Food and Drug Administration for selling Memantine Hydrochloride extended-release capsules, a generic version of Allergan’s Namenda XR capsules.Namenda XR extended-release capsules are approved by the...
Kilitch Drugs to set up plant in Ethiopia Kilitch Drugs (India) Ltd said its unit Kilitch Estro Biotech Plc acquired land for the installation of a pharma plant in Ethiopia.4317.5 sq. mtrs of land was allotted at Oromia special zone by the Bureau of Rural Land and Environmental Protection, Federal Democratic Republic...
Packaged food market reached $51 mn mark in 2015: Study Clocking a compounded annual growth rate (CAGR) of about 16 per cent, the packaged food market in India is expected to have crossed $51.5 million (mn) mark in 2015 as against $25 million in 2010, noted a recent ASSOCHAM-TechSci Research joint study.“In wake of the increasing ...
Suven Life Sciences gets two product patents in India and Japan Drug manufacturer Suven Life Sciences Ltd said it got two product patents in India and Japan for to a new compound for the treatment of disorders associated with Neurodegenerative diseases.The patents are valid through 2026-2032.The granted claims include a class of selec...
Marksans Pharma gets USFDA approval for sale of anti-allergy drug Marksans Pharma Limited, an Indian pharmaceutical company, said it has received approval from the USFDA for the sale sale of its Loratadine Liquid Filled Capsules 10 mg in the US market.Loratadine is an antihistamine that reduces the effects of natural chemical histamine in t...
Lincoln Pharma develops oral spray version of Ondansetron anti-nausea drug Lincoln Pharmaceuticals Ltd said it developed and launched an oral spray version of Ondansetron anti-nausea drug.Ondansetron is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy), radiation therapy and also in the prevention and treatment for n...
Aurobindo Pharma to launch HIV drug in Africa this year, gets tentative FDA nod Aurobindo Pharma Limited, a pharmaceutical manufacturing company based in Hyderabad, said it received a tentative approval for HIV drug Dolutegravir from US Food & Drug Administration.It is the first FDA approval of a generic version of Dolutegravir. Through a tie up w...
Syngene International buys systems biology and pharma services assets of Strand Life Sciences Syngene International Ltd., Asia’s largest contract research organization, said it has purchased assets of Strand Life Sciences related to systems biology, Heptox and Pharma Bioinformatics services.Financial details of the deal were not disclosed.The acquisition includes ...
Zydus Cadila ties up with Takeda Pharmaceuticals for chikungunya vaccine Zydus Cadila, a global healthcare provider, and Takeda Pharmaceutical Company Limited, one of the world´s largest pharmaceutical companies, announced a partnership to develop vaccine for chikungunya, an emerging infectious disease.The broadbased agreement includes early stage...